Merck Frosst
Patients & Caregivers Contact Us Français
Patients & CaregiversContact UsFrançais
Home

Patients and Caregivers - Health info for you and your family

Healthcare Professionals - Resources for Canadian physicians

Better Care, Healthy Communities

Products - Our medecines

Newsroom

3D Anatomical Models


 This site was updated on
October 26, 2011.

RX&D Member RECYC-QUÉBEC
 
Montréal InVivo - Metro montréal's life sciences cluster
 
From discovery to medicine - Singulair® Experience

What’s new?


Boceprevir based therapy cleared the hepatitis C virus in 38 per cent of patients who had failed to respond to previous treatment

For more information, click here.

Merck Canada to bring state-of-the-art mobile personal health record technology to Canadian doctors

For more information, click here.

Merck Canada confirms its Pointe Claire facility as a Centre of Excellence for manufacturing liquids, ointments and creams

For more information, click here.

Boceprevir based therapy cleared the hepatitis C virus in 70 percent of patients coinfected with hepatitis C and HIV-1

For more information, click here.

VICTRELIS™ Approved in Canada: First in new class of drugs to significantly improve clearance of chronic hepatitis C virus from the body

For more information, click here.

Important information regarding SINEMET® and SINEMET® CR.

For more information, click here.

Merck Announces New Name for its Animal Health Division

For more information, click here.

Gardasil® Approved To Help Prevent Anal Cancer In Women And Men

For more information, click here.

Merck Applauds This Year's Bourse Fernand-Seguin Recipients

For more information, click here.

Merck Canada Extends Community Action Day across Canada

For more information, click here.

New Formulation of EMEND® IV Approved in Canada

For more information, click here.

New Data Reinforces GARDASIL'S Safety Profile

For more information, click here.

Health Canada Approves Gardasil® for Women Up to Age 45

For more information, click here.

Merck Canada - A 20-Year Partnership With The Science Fairs

For more information, click here.

The New England Journal of Medicine Publishes Pivotal Studies Showing Potential of New Investigational Treatment for Chronic Infection with Hepatitis C Virus Genotype 1

For more information, click here.

Merck Canada Invests $6.8 Million in Research in Quebec

For more information, click here.

Public communication regarding PEGETRON® REDIPEN®

For more information, click here.

Important information regarding PEGETRON® REDIPEN®

For more information, click here.

New England Journal of Medicine Publishes Efficacy and Safety Data for Gardasil® in Males

For more information, click here.

Meta-analysis of interferon alfa studies cited as “Notable Advance” in BEST OF 2010 REPORT BY AMERICAN SOCIETY OF CLINICAL ONCOLOGY - Improved survival in patients with deadliest form of skin cancer

For more information, click here.

Merck Canada Invests $5 Million in Quebec Consortium for Drug Discovery to Support Biopharmaceutical Research

For more information, click here.

Recent Features


Terms and Conditions for Sales

Click here click here to access Terms and Conditions of Sales.

3D Anatomical Models
3D Anatomical Models
New 3D anatomical models which will allow you to explore all corners of the human body. You can move these anatomical models and raise the flesh to have a full 3D effect simply by a twist of the mouse!
Click here to find out!
If you never gave chickenpox a second thought… Think again. If you never gave chickenpox a second thought… Think again.

There is something you can do.
Help protect your child against chickenpox.
Click here to find out!
A New Look at AsthmaA New Look at Asthma

Education may be your key to taking control of your asthma. Visit our new asthma site to learn more about asthma and the treatments available.
VIOXX<sup>®</sup> Information CenterVIOXX® Information Center

Click here to access VIOXX® Information Center.

This site is for residents of Canada. / This site was updated on October 26, 2011.